Clinical trial · Interventional
Prognostic and Predictive Biomarkers in Ovarian Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators therefore propose to conduct a biological study of prospectively collected patient tumour samples, ascites, blood and other residual samples (feces, urine, vaginal smear) throughout the disease course where markers (at diagnosis and their change with treatment) will be correlated to outcome in order to investigate how genetic diversity in OC prior to treatment and adaptation following treatment contribute to chemotherapy resistance. In addition freshly collected ascitic samples (and tumour samples) will be subjected to ex vivo DNA repair functional assays and isolated in primary culture (and established as xenografts) for target validation experiments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with ovarian cancer
- interventionNames
- Procedure: Blood sample
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- Correlation of baseline biomarkers with PFS will occur at 12 months following last patient inclusion
- description
- up to 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. New patient with a diagnosis of OC, or 2. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center presenting with progressive disease, and consenting to CT guided biopsy of relapsed disease, or 3. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center scheduled for surgery for relapsed disease. 4. Signed informed consent 5. Age ≥ 18 6. Patient affiliated to a social security regimen or beneficiary of the same Exclusion Criteria: 1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral treatment; 2. Coagulation abnormalities that contra-indicates the biopsy
References
Publications (1)
- DERIVEDKfoury M, Bonnet C, Delanoy N, Howarth K, Marzac C, Rouleau E, Micol JB, Leary A. Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas. Int J Gynecol Cancer. 2024 Nov 4;34(11):1836-1839. doi: 10.1136/ijgc-2024-005581. PMID 39313297